FDA Grants Breakthrough Device Designation to Freenome's AI-Powered Lung Cancer Blood Test

The U.S. Food and Drug Administration on August 12, 2026 granted Breakthrough Device Designation to Freenome's SimpleScreen Lung, an AI/ML-powered multiomic blood test designed to detect early signals of lung cancer in adults ages 50 to 80 at high risk who are not currently participating in guideline-recommended screening, the company announced. The designation comes roughly two weeks after the FDA approved Freenome's colorectal cancer test, SimpleScreen CRC, marking the Brisbane, California-based company as one of the fastest-moving players in AI-driven oncology screening.

How SimpleScreen Lung Works

SimpleScreen Lung uses Freenome's methylation and next-generation sequencing platform to combine methylation and proteomics with an AI/ML classifier that analyzes a standard blood draw. Positive findings suggest a potential signal for lung cancer and should be followed up with confirmatory imaging. The Breakthrough Device Designation gives Freenome expedited FDA review and greater interactive engagement during the development process — a status reserved for devices that could provide more effective diagnosis of life-threatening conditions.

The Colorectal Precedent

The breakthrough designation follows the FDA's July 27 approval of SimpleScreen CRC, the company's first blood test for colorectal cancer screening. That approval — the first for a blood-based CRC screening test — explicitly used Freenome's cell-free DNA platform and supports screening in the 45+ age group. Abbott has agreed to commercialize the colorectal test in the United States. "The two FDA wins in two weeks confirm that the platform is real and the pipeline is going to be deep," Freenome Chief Medical Officer Lance Baldo told investors on the August 12 announcement call.

Why It Matters

Lung cancer is the deadliest cancer in the United States, killing roughly 125,000 Americans each year, in part because more than half of cases are diagnosed at a late stage. A blood-based screening option for the high-risk population — particularly those unwilling or unable to undergo low-dose CT screening — could meaningfully shift the early-detection curve. Freenome's lung test is in the same year as competing efforts from Guardant Health, Exact Sciences, and a Darryl Strawberry-backed startup called Early Diagnostics, but Freenome's methylation-plus-proteomics approach is the most differentiated. The Breakthrough Device Designation suggests the FDA sees the platform as a path to a wider lung-cancer screening paradigm that complements imaging rather than replacing it.